CDK4/CDK6 Inhibitors Synergize with Midostaurin, Avapritinib, and Nintedanib in Inducing Growth Inhibition in KIT D816V+ Neoplastic Mast Cells

Simple Summary Advanced systemic mastocytosis (AdvSM) is a rare malignant disease with a poor prognosis due to the drug resistance of neoplastic mast cells. We found that drugs targeting the cell cycle regulators CDK4 and CDK6 profoundly suppress the growth and survival of neoplastic mast cells. Furthermore, these drugs can overcome resistance against KIT D816V-targeting drugs, including midostaurin, in neoplastic mast cells. Finally, the CDK4/CDK6 inhibitors applied induced apoptosis in CD34+/CD38− stem cells in AdvSM. Based on these results, we believe that CDK4/CDK6 inhibition may be a new and interesting therapeutic approach with curative potential for AdvSM. Whether combinations of KIT D816-targeting drugs and CDK4/CDK6 inhibitors can induce long-term remission in patients with AdvSM remains to be determined in clinical trials. Abstract In most patients with advanced systemic mastocytosis (AdvSM), neoplastic mast cells (MC) express KIT D816V. However, despite their disease-modifying potential, KIT D816V-targeting drugs, including midostaurin and avapritinib, may not produce long-term remissions in all patients. Cyclin-dependent kinase (CDK) 4 and CDK6 are promising targets in oncology. We found that shRNA-mediated knockdown of CDK4 and CDK6 results in growth arrest in the KIT D816V+ MC line HMC-1.2. The CDK4/CDK6 inhibitors palbociclib, ribociclib, and abemaciclib suppressed the proliferation in primary neoplastic MC as well as in all HMC-1 and ROSA cell subclones that were examined. Abemaciclib was also found to block growth in the drug-resistant MC line MCPV-1, whereas no effects were seen with palbociclib and ribociclib. Anti-proliferative drug effects on MC were accompanied by cell cycle arrest. Furthermore, CDK4/CDK6 inhibitors were found to synergize with the KIT-targeting drugs midostaurin, avapritinib, and nintedanib in inducing growth inhibition and apoptosis in neoplastic MCs. Finally, we found that CDK4/CDK6 inhibitors induce apoptosis in CD34+/CD38− stem cells in AdvSM. Together, CDK4/CDK6 inhibition is a potent approach to suppress the growth of neoplastic cells in AdvSM. Whether CDK4/CDK6 inhibitors can improve clinical outcomes in patients with AdvSM remains to be determined in clinical trials.

[1]  S. Verstovsek,et al.  Safety and efficacy of avapritinib in advanced systemic mastocytosis: the phase 1 EXPLORER trial , 2021, Nature Medicine.

[2]  J. Panse,et al.  Efficacy and safety of avapritinib in advanced systemic mastocytosis: interim analysis of the phase 2 PATHFINDER trial , 2021, Nature Medicine.

[3]  Jing Tang,et al.  SynergyFinder Plus: Toward Better Interpretation and Annotation of Drug Combination Screening Datasets , 2021, bioRxiv.

[4]  D. Rassl,et al.  Inhibition of mast cells: a novel mechanism by which nintedanib may elicit anti-fibrotic effects , 2020, Thorax.

[5]  P. Roberts,et al.  Chemotherapy and CDK4/6 Inhibitors: Unexpected Bedfellows , 2020, Molecular Cancer Therapeutics.

[6]  Qiaojun He,et al.  Intrinsic and acquired resistance to CDK4/6 inhibitors and potential overcoming strategies , 2020, Acta Pharmacologica Sinica.

[7]  F. Awan,et al.  Midostaurin improves quality of life and mediator-related symptoms in advanced systemic mastocytosis. , 2020, The Journal of allergy and clinical immunology.

[8]  S. Mustjoki,et al.  Nintedanib Targets KIT D816V Neoplastic Cells Derived from Induced Pluripotent Stem cells of Systemic Mastocytosis , 2020, bioRxiv.

[9]  T. George,et al.  New Developments in Diagnosis, Prognostication, and Treatment of Advanced Systemic Mastocytosis. , 2020, Blood.

[10]  Sohita Dhillon.  Avapritinib: First Approval , 2020, Drugs.

[11]  D. Meyerholz,et al.  RABL6A Is an Essential Driver of MPNSTs that Negatively Regulates the RB1 Pathway and Sensitizes Tumor Cells to CDK4/6 Inhibitors , 2020, Clinical Cancer Research.

[12]  M. Malumbres,et al.  CDK4/6 Inhibitors Impair Recovery from Cytotoxic Chemotherapy in Pancreatic Adenocarcinoma. , 2020, Cancer cell.

[13]  K. Sotlar,et al.  New developments in the field of mastocytosis and mast cell activation syndromes: a summary of the Annual Meeting of the European Competence Network on Mastocytosis (ECNM) 2019 , 2019, Leukemia & lymphoma.

[14]  M. Triggiani,et al.  International prognostic scoring system for mastocytosis (IPSM): a retrospective cohort study. , 2019, The Lancet. Haematology.

[15]  T. Lion,et al.  CDK4/CDK6 inhibition as a novel strategy to suppress the growth and survival of BCR-ABL1T315I+ clones in TKI-resistant CML , 2019, EBioMedicine.

[16]  Olivier Hermine,et al.  Faculty Opinions recommendation of Mastocytosis: 2016 updated WHO classification and novel emerging treatment concepts. , 2019, Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature.

[17]  J. Zeidner,et al.  Cyclin-dependent kinase (CDK) 9 and 4/6 inhibitors in acute myeloid leukemia (AML): a promising therapeutic approach , 2019, Expert opinion on investigational drugs.

[18]  M. Benelli,et al.  Mechanisms of Resistance to CDK4/6 Inhibitors: Potential Implications and Biomarkers for Clinical Practice , 2019, Front. Oncol..

[19]  M. Jacobson,et al.  ATP-competitive inhibitors midostaurin and avapritinib have distinct resistance profiles in exon 17-mutant KIT. , 2019, Cancer research.

[20]  T. Hung,et al.  Avapritinib: A Selective Inhibitor of KIT and PDGFRα that Reverses ABCB1 and ABCG2-Mediated Multidrug Resistance in Cancer Cell Lines. , 2019, Molecular pharmaceutics.

[21]  M. Meyerson,et al.  A Functional Landscape of Resistance to MEK1/2 and CDK4/6 Inhibition in NRAS-Mutant Melanoma. , 2019, Cancer research.

[22]  A. Gardino,et al.  Inhibitory effects of midostaurin and avapritinib on myeloid progenitors derived from patients with KIT D816V positive advanced systemic mastocytosis , 2019, Leukemia.

[23]  G. Stefanzl,et al.  Identification of a Leukemia-Initiating Stem Cell in Human Mast Cell Leukemia , 2019, Leukemia.

[24]  J. Gotlib,et al.  The new tool "KIT" in advanced systemic mastocytosis. , 2018, Hematology. American Society of Hematology. Education Program.

[25]  W. Hofmann,et al.  Incidence and prognostic impact of cytogenetic aberrations in patients with systemic mastocytosis , 2018, Genes, chromosomes & cancer.

[26]  G. Stefanzl,et al.  The KIT and PDGFRA switch-control inhibitor DCC-2618 blocks growth and survival of multiple neoplastic cell types in advanced mastocytosis , 2018, Haematologica.

[27]  T. Fojo,et al.  CDK4/6 Inhibition as a therapeutic strategy in breast cancer: palbociclib, ribociclib, and abemaciclib. , 2017, Seminars in oncology.

[28]  H. Kluin-Nelemans,et al.  Midostaurin: a magic bullet that blocks mast cell expansion and activation , 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

[29]  J. Gotlib.  Tyrosine Kinase Inhibitors in the Treatment of Eosinophilic Neoplasms and Systemic Mastocytosis. , 2017, Hematology/oncology clinics of North America.

[30]  P. Neven,et al.  MONARCH 2: Abemaciclib in Combination With Fulvestrant in Women With HR+/HER2- Advanced Breast Cancer Who Had Progressed While Receiving Endocrine Therapy. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[31]  P. Valent,et al.  Mastocytosis: 2016 updated WHO classification and novel emerging treatment concepts. , 2017, Blood.

[32]  J. Zuber,et al.  CCL2 is a KIT D816V-dependent modulator of the bone marrow microenvironment in systemic mastocytosis. , 2017, Blood.

[33]  E. Winer,et al.  Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer. , 2016, The New England journal of medicine.

[34]  H. Kluin-Nelemans,et al.  Advanced systemic mastocytosis: from molecular and genetic progress to clinical practice , 2016, Haematologica.

[35]  Ping Chen,et al.  Spectrum and Degree of CDK Drug Interactions Predicts Clinical Performance , 2016, Molecular Cancer Therapeutics.

[36]  R. Finn,et al.  Treating cancer with selective CDK4/6 inhibitors , 2016, Nature Reviews Clinical Oncology.

[37]  F. Awan,et al.  Efficacy and Safety of Midostaurin in Advanced Systemic Mastocytosis. , 2016, The New England journal of medicine.

[38]  J. Infante,et al.  Targeting CDK4/6 in patients with cancer. , 2016, Cancer treatment reviews.

[39]  G. Superti-Furga,et al.  Target interaction profiling of midostaurin and its metabolites in neoplastic mast cells predicts distinct effects on activation and growth , 2016, Leukemia.

[40]  Massimo Triggiani,et al.  Cutaneous manifestations in patients with mastocytosis: Consensus report of the European Competence Network on Mastocytosis; the American Academy of Allergy, Asthma & Immunology; and the European Academy of Allergology and Clinical Immunology. , 2016, The Journal of allergy and clinical immunology.

[41]  Krister Wennerberg,et al.  Corrigendum to “Searching for drug synergy in complex dose–response landscapes using an interaction potency model” [Comput. Struct. Biotechnol. J. 13 (2015) 504–513] , 2017, Computational and structural biotechnology journal.

[42]  R. Pazdur,et al.  FDA Approval: Palbociclib for the Treatment of Postmenopausal Patients with Estrogen Receptor–Positive, HER2-Negative Metastatic Breast Cancer , 2015, Clinical Cancer Research.

[43]  P. Valent,et al.  Current treatment options in patients with mastocytosis: status in 2015 and future perspectives , 2015, European journal of haematology.

[44]  C. Boshoff,et al.  Molecular Pathways: Targeting the Cyclin D–CDK4/6 Axis for Cancer Treatment , 2015, Clinical Cancer Research.

[45]  R. Arceci,et al.  Targeting cell cycle regulators in hematologic malignancies , 2015, Front. Cell Dev. Biol..

[46]  M. Triggiani,et al.  KIT mutation analysis in mast cell neoplasms: recommendations of the European Competence Network on Mastocytosis , 2015, Leukemia.

[47]  M. Malumbres,et al.  CDK6 as a key regulator of hematopoietic and leukemic stem cell activation. , 2015, Blood.

[48]  D. Heitjan,et al.  CDK 4/6 Inhibitor Palbociclib (PD0332991) in Rb+ Advanced Breast Cancer: Phase II Activity, Safety, and Predictive Biomarker Assessment , 2014, Clinical Cancer Research.

[49]  L. Pagano,et al.  Hematopoietic stem-cell transplantation for advanced systemic mastocytosis. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[50]  K. Sotlar,et al.  CD52 is a molecular target in advanced systemic mastocytosis , 2014, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[51]  T. Rülicke,et al.  A new human mast cell line expressing a functional IgE receptor converts to tumorigenic growth by KIT D816V transfection. , 2014, Blood.

[52]  L. Gelbert,et al.  Semi-Mechanistic Pharmacokinetic/Pharmacodynamic Modeling of the Antitumor Activity of LY2835219, a New Cyclin-Dependent Kinase 4/6 Inhibitor, in Mice Bearing Human Tumor Xenografts , 2014, Clinical Cancer Research.

[53]  P. Dubreuil,et al.  ASXL1 but Not TET2 Mutations Adversely Impact Overall Survival of Patients Suffering Systemic Mastocytosis with Associated Clonal Hematologic Non-Mast-Cell Diseases , 2014, PloS one.

[54]  A. Kohlmann,et al.  Comprehensive mutational profiling in advanced systemic mastocytosis. , 2013, Blood.

[55]  A. Reiter,et al.  Synergistic growth-inhibitory effects of ponatinib and midostaurin (PKC412) on neoplastic mast cells carrying KIT D816V , 2013, Haematologica.

[56]  S. T. Olalla Saad,et al.  Single Nucleotide Polymorphism Array Lesions, TET2, DNMT3A, ASXL1 and CBL Mutations Are Present in Systemic Mastocytosis , 2012, PloS one.

[57]  W. Pickl,et al.  Polo-like kinase-1 as a novel target in neoplastic mast cells: demonstration of growth-inhibitory effects of small interfering RNA and the Polo-like kinase-1 targeting drug BI 2536 , 2011, Haematologica.

[58]  D. Maric,et al.  Clonal analysis of NRAS activating mutations in KIT-D816V systemic mastocytosis , 2011, Haematologica.

[59]  X. Graña,et al.  Proliferative suppression by CDK4/6 inhibition: complex function of the retinoblastoma pathway in liver tissue and hepatoma cells. , 2010, Gastroenterology.

[60]  J. Dering,et al.  PD 0332991, a selective cyclin D kinase 4/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitro , 2009, Breast Cancer Research.

[61]  D. Fabbro,et al.  Synergistic growth-inhibitory effects of two tyrosine kinase inhibitors, dasatinib and PKC412, on neoplastic mast cells expressing the D816V-mutated oncogenic variant of KIT , 2007, Haematologica.

[62]  D. Fabbro,et al.  PKC412 inhibits in vitro growth of neoplastic human mast cells expressing the D816V-mutated variant of KIT: comparison with AMN107, imatinib, and cladribine (2CdA) and evaluation of cooperative drug effects. , 2006, Blood.

[63]  N. Pryer,et al.  Specific inhibition of cyclin-dependent kinase 4/6 by PD 0332991 and associated antitumor activity in human tumor xenografts. , 2004, Molecular cancer therapeutics.

[64]  H. Kluin-Nelemans,et al.  Cladribine therapy for systemic mastocytosis. , 2003, Blood.

[65]  B. Longley,et al.  Effects of tyrosine kinase inhibitor STI571 on human mast cells bearing wild-type or mutated c-kit. , 2003, Experimental hematology.

[66]  J. Bennett,et al.  Aggressive systemic mastocytosis and related mast cell disorders: current treatment options and proposed response criteria. , 2003, Leukemia research.

[67]  A. Órfão,et al.  Mastocytosis: current concepts in diagnosis and treatment , 2002, Annals of Hematology.

[68]  K. Lennert,et al.  Diagnostic criteria and classification of mastocytosis: a consensus proposal. , 2001, Leukemia research.

[69]  P. Valent,et al.  Diagnosis of mastocytosis: general histopathological aspects, morphological criteria, and immunohistochemical findings. , 2001, Leukemia research.

[70]  J. Bernhard,et al.  Mastocytosis , 1997, The Lancet.

[71]  Y. Suzuki,et al.  Identification of a point mutation in the catalytic domain of the protooncogene c-kit in peripheral blood mononuclear cells of patients who have mastocytosis with an associated hematologic disorder. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[72]  R. Weinberg,et al.  The retinoblastoma protein and cell cycle control , 1995, Cell.

[73]  L. Ashman,et al.  Identification of mutations in the coding sequence of the proto-oncogene c-kit in a human mast cell leukemia cell line causing ligand-independent activation of c-kit product. , 1993, The Journal of clinical investigation.

[74]  D. Metcalfe,et al.  Classification and diagnosis of mastocytosis: current status. , 1991, The Journal of investigative dermatology.

[75]  G. Dewald,et al.  Establishment of an immature mast cell line from a patient with mast cell leukemia. , 1988, Leukemia research.

[76]  T. Chou,et al.  Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. , 1984, Advances in enzyme regulation.